Abstract
IntroductionShingrix, an effective adjuvanted, recombinant herpes zoster vaccine (RZV), has been available since 2018. Immunocompromised patients are known to be predisposed to vaccine failure. In-vitro testing of immunological surrogates of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have